SCHEMBL4664376

SCHEMBL4664376

O=S(=O)(Nc1ccc(Nc2cc(-c3ccc4[nH]ccc4c3)ncn2)cc1)c1ccc(F)cc1F

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRF1 P14222 1/20 0.56
ABL1 P00519 2/20 0.56
BCR P11274 2/20 0.56
KIT P10721 1/20 0.44
NEK2 P51955 1/20 0.43
NEK5 Q6P3R8 1/20 0.43
NEK1 Q96PY6 1/20 0.43
PLK2 Q9NYY3 1/20 0.43
USP2 O75604 3/20 0.42
CYP1A2 P05177 2/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2D6 P10635 2/20 0.42
CYP2C9 P11712 2/20 0.42
CYP2C19 P33261 2/20 0.42
CLK4 Q9HAZ1 2/20 0.42
TP53 P04637 2/20 0.42
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 1/20 0.42
GLA P06280 1/20 0.42
ALOX15 P16050 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4667463 0.90 ABL1 (0.57) PRF1ABL1BCRUSP2CYP1A2
Formic Acid SCHEMBL4665712 0.87 ABL1 (0.51) PRF1ABL1BCRKITUSP2
SCHEMBL4666151 0.86 CYP1A2 (0.56) ABL1BCRKITUSP2CYP1A2
SCHEMBL4667404 0.85 ABL1 (0.56) ABL1BCRKITUSP2CYP1A2
SCHEMBL4667424 0.85 ABL1 (0.58) PRF1ABL1BCRUSP2CYP1A2
SCHEMBL4663770 0.83 USP2 (0.51) ABL1BCRKITUSP2CYP1A2
SCHEMBL4666113 0.79 ABL1 (0.49) ABL1BCRKITUSP2CYP1A2
SCHEMBL4664333 0.78 TP53 (0.49) ABL1BCRUSP2CYP1A2CYP3A4
SCHEMBL4663875 0.77 CYP1A2 (0.55) ABL1BCRKITUSP2CYP1A2
SCHEMBL4665802 0.76 CYP1A2 (0.50) ABL1BCRKITUSP2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 PRF1 3924/4885ABL1 24/4885BCR 402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.